Adding GLP-1 to a med spa: telehealth prescriber or in-house

How to add GLP-1 to a med spa is a question that arrives with a lot of pressure behind it: existing clients are asking, a competitor across town has a sign in the window, and aesthetic revenue is flat. This post lays out the three ways a spa can offer a medical weight loss program, who is allowed to prescribe under each, where the medication legally comes from now that the FDA has ended the shortage, why dispensing in the spa is the piece that causes the most trouble, and what a patient is worth in a labelled hypothetical. The short version of the argument is that telehealth prescribing with pharmacy-to-patient delivery is the fastest compliant path for most spas, because it removes the three problems that trip spas up: in-house dispensing, sourcing and prescriber employment.

Three ways a med spa can offer GLP-1

The first is a referral. The spa points clients at an outside clinic or telehealth service and takes no part in the medical side. It costs nothing and earns nothing, and in many states a payment for the referral itself is a fee-splitting or anti-kickback problem, so it stays a courtesy. The client relationship for the medical program belongs to someone else.

The second is in-house. The spa's medical director or a hired prescriber sees the client in the spa, the spa buys medication from a pharmacy or outsourcing facility, stores it, and a nurse administers or dispenses it on site. This is the model most spas picture and it carries the most obligations: a prescriber who is properly engaged and supervising, a dispensing permit where the state requires one, cold storage, lot tracking, labelling, a formal relationship with the pharmacy, and a corporate structure that keeps the spa's owner out of clinical decisions if the owner is not a physician.

The third is a telehealth program under the spa's brand. The client signs up on a branded page, is seen by a licensed telehealth provider, and a pharmacy ships the medication to the client's home in cold-chain packaging. The spa does the marketing, the front-desk conversation and the body-composition and aesthetic follow-up, and keeps the client relationship. Nothing is stored or dispensed at the spa. This is the arrangement Tessic Health runs for med spa clients, and the rest of this post explains why it removes the pieces that make the second model expensive.

Who can prescribe, and the corporate practice rule

GLP-1 medications are prescription drugs and only a licensed prescriber can order them: a physician, a nurse practitioner or a physician assistant, depending on the state. Nurse practitioners can prescribe independently in some states and need a collaborating or supervising physician in others; the American Association of Nurse Practitioners publishes the state-by-state map, and the count changes, so this post does not give one. A registered nurse, an aesthetician, a medical assistant or the spa owner cannot prescribe, and a nurse can administer or dispense only under a valid order from someone who can.

The second rule is the corporate practice of medicine, usually shortened to CPOM. In states that enforce it, a business owned by non-physicians cannot employ physicians to practice medicine or control their clinical decisions. There is no official count of how many states enforce it and the strictness varies, so the safe assumption is that it applies until a lawyer in the spa's state says otherwise. The standard solution is the one telehealth brands use: a professional corporation owned by a licensed physician holds the clinical side, and a management services organization, an MSO, owned by the spa's owner holds the brand, the marketing, the technology and the non-clinical staff, with a management agreement between the two. A spa that already has a medical director may already have a version of this. A spa that is paying a physician a flat monthly fee to lend a license to a nurse injector often does not, and adding prescription medication is the moment that gap gets noticed.

Under the telehealth model, the prescriber question is largely answered by the arrangement. The telehealth provider is licensed in the client's state, the professional corporation is drafted for the owner, and the spa never becomes the prescriber's employer. The do I need a medical license guide covers the general question; the short answer for a spa is no, provided the structure is right.

Sourcing after the shortage ended

For roughly two years, most of the GLP-1 medication sold outside the branded channel was compounded semaglutide or tirzepatide, produced under the FDA's shortage-era flexibility. That window closed on a published schedule. FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. The agency's enforcement discretion for compounders ended on the dates it set: for tirzepatide, February 18, 2025 for 503A compounding pharmacies and March 19, 2025 for 503B outsourcing facilities; for semaglutide, 503B facilities were given until May 22, 2025. The FDA's page on the subject, updated April 1, 2026, states that neither drug is on the shortage list or on the list of bulk drug substances that 503B facilities may compound from.

Two further developments narrow the compounded route. On April 30, 2026 the FDA proposed formally excluding semaglutide, tirzepatide and liraglutide from the 503B bulk substances list; the comment period closed June 29, 2026 and, as of this post, a final rule had not been confirmed. And in 2026 the Fifth Circuit upheld the FDA's decision to remove semaglutide and tirzepatide from the shortage list against a challenge by the Outsourcing Facilities Association, according to a law-firm summary of the ruling.

What this means for a spa is that a 503A pharmacy, the kind that compounds for an individual patient under a prescription, may still prepare a compounded version only where a prescriber documents a clinical reason that particular patient cannot use the commercially available product, and that reason has to be real and patient-specific. Copies made because they are cheaper are what the FDA's enforcement letters target. The branded products, meanwhile, became more reachable for cash-pay patients over 2025: CNBC reported in March 2025 that the manufacturer of Wegovy began selling it to self-pay patients at $499 a month through a direct channel, and the press reported an oral form approved December 22, 2025 and offered through telehealth at about $149 a month. A spa that sources through a pharmacy network with wholesale pricing and no markup can put branded product in front of a client at a price that would have been hard to reach in 2024.

That is the second reason the telehealth model wins for a spa: the pharmacy relationship, the 503A and 503B distinction, the documentation of clinical need and the cold chain are all held by the pharmacy network, and the spa never takes title to the drug.

Dispensing in the spa versus pharmacy to patient

Prescribing and dispensing are different licensed acts, and the difference is where most spa programs go wrong. Prescribing is the clinical order; dispensing is handing a labelled supply of the drug to the patient to take away. In most states a prescriber can dispense from their own office only with a separate permit, specific labelling, a dispensing log and storage that meets the state pharmacy board's rules, and some states restrict physician dispensing more tightly than that. A spa handing a client a vial and syringes is dispensing whether it calls it that or not. The dispensing versus prescribing glossary entry goes further into the distinction.

In-spa dispensing also creates inventory: capital tied up in refrigerated stock, waste when a client stops, a cold-chain failure when a fridge alarm is ignored over a weekend, and a lot-tracking obligation when a recall notice arrives. Pharmacy-to-patient fulfillment moves every one of these to a licensed pharmacy. The pharmacy fills against a patient-specific prescription, labels it, ships it cold-chain to the client's door, and the spa's exposure to the drug is a tracking number. That is the third problem the telehealth model removes.

The first visit and follow-ups

Under the telehealth model, the clinical path is fixed by the providers and the spa fits around it. The client completes an intake questionnaire covering contraindications, medication history and weight verification. A licensed provider reviews it, orders labs where the protocol requires them, and either prescribes, asks for a synchronous visit, or declines. Follow-ups run on the titration protocol, with a provider check before each dose step and a fixed cadence of reviews. None of this happens in the spa and none of it is the spa's to design, which is the point: the standard of care is owned by the licensed people.

What the spa owns is the relationship around it. The front desk can enroll the client, the spa can book body-composition measurements and progress photos on the same schedule as the medical check-ins, and the client experiences one brand. The scheduled check-ins give the spa a reason to see the client every month that a standalone aesthetic client does not offer.

Pairing with aesthetic services

The commercial reason spas want this program is that a client losing a significant amount of weight becomes a candidate for services the spa already sells. Skin laxity in the face, neck, abdomen and arms, volume loss in the face, and body contouring for areas that resist are the aesthetic conversations that follow weight loss, and a spa running the program is the one in the room when they come up.

Two rules of restraint. Aesthetic recommendations should come from the spa's aesthetic staff after the weight has come off, and should not be bundled into the medical enrollment, because a program that looks like it exists to sell fillers will be read that way by a board. And marketing for the weight loss program is subject to the same platform and regulator rules as any prescription-drug advertising: Google requires LegitScript or NABP certification to run prescription-drug ads, and Meta requires weight loss ads to target adults 18 and over and limits before-and-after images, according to each platform's published policy pages. Before-and-after photos are a staple of spa marketing, and a medication result presented as an aesthetic one is a frequent source of complaints.

What each patient is worth

The example below is a labelled hypothetical; the prices and costs are round numbers chosen to show the shape, and a spa should replace every one with its own. Assume a monthly program price of $299 covering medication, provider oversight and the spa's check-ins. Assume the medication and cold-chain shipping cost the program $150 a month at wholesale with no markup, and that the provider bills a flat $25 per completed consult, with roughly four consults in the first six months. Assume the client came from the spa's existing book, so acquisition cost is small, say $40 in front-desk time and a text sequence.

Over six months the client pays $1,794. Medication costs $900, consults $100, acquisition $40. The program contributes about $754, before the spa's own staff time on check-ins and before any aesthetic services the client buys along the way. Change the retention to four months and contribution falls to about $460, which is the same lesson every telehealth operator learns: the money is in the months after the first. A spa with a warm client list starts with a lower acquisition cost than a cold-traffic telehealth brand, but only the follow-up cadence keeps the client past month three.

The cost structure matters here as it does everywhere. A platform that charges a percentage of program revenue takes a share of the contribution the spa's own client list generated. Tessic Health's terms for a spa are the published ones: $25 flat per completed consult, 0% medication markup, no revenue share on any plan, month to month after a one-time setup fee, with plans from $1,000 a month. The med spa page sets out how the program fits an existing spa and the weight loss launch page covers the setup.

A spa handing a client a vial and syringes is dispensing whether it calls it that or not, and the pharmacy board will use its own word for it.

Questions operators ask

Can the spa's existing medical director prescribe GLP-1 to spa clients? In most states yes, if the director is actually seeing the client, documenting a patient-specific decision, and is engaged through a structure that survives the state's corporate practice rule. A director who signs off on nurse injectors monthly and has never met the client is not a defensible prescriber for a chronic medication.

Can the spa buy compounded semaglutide and keep it in stock? Under the FDA's current position, compounded copies of a commercially available drug are only permitted with a patient-specific clinical reason documented by the prescriber, and stocking a supply in advance of any patient is the opposite of patient-specific. A spa that was stocking compounded product before the shortage ended should treat that as a closed chapter.

Can the program run under the spa's own name? Yes, under either the in-house or the telehealth model, provided the clinical entity is properly structured and the marketing does not claim that the spa itself prescribes. The telehealth model is white-label by design: the storefront, the patient portal and the messages carry the spa's brand, and the licensed providers and pharmacy sit behind it.

How long does it take? The in-house version needs the structure, a prescriber, a dispensing permit where required, pharmacy relationships and storage before the first client, which is measured in months. Plugging into an operating telehealth arrangement is limited mostly by how fast the spa's legal structure and LegitScript application can be completed.